Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3463158 A
Type de publicationOctroi
Date de publication26 août 1969
Date de dépôt9 janv. 1967
Date de priorité31 oct. 1963
Numéro de publicationUS 3463158 A, US 3463158A, US-A-3463158, US3463158 A, US3463158A
InventeursEdward Emil Schmitt, Rocco Albert Polistina
Cessionnaire d'origineAmerican Cyanamid Co
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Polyglycolic acid prosthetic devices
US 3463158 A
Images(4)
Previous page
Next page
Description  (Le texte OCR peut contenir des erreurs.)

Aug. 26, 1969 E. SCHMITT ET AL 3,463,158

. POLYGLYCOLIC ACID PROSTHETIC DEVICES Filed Jan. 9. 1967 4 Sheets-Sheet 1 2l-N0/V-A BSORBA EL .5 22-4 BSORBA BL E F-r- 7-2- 'FE'F-z Fr -,1,

1:1 /00 NON- ABSORBABLE m 75 NON-ABSORBABL 25 PGA m 50 NON-ABSORBABLE- 50% PGA IE- 25% NON-ABSORBABLE-75 PGA INVENTORS. EDWARD EM/L SCHM/TT ROCICO ALBERT POL/.ST/NA ATTORNEY Aug. 26, 1969 E. E. SCHMITT ET AL 3,463,158

POLYGLYCOLIC ACID PROSTHETIC DEVICES Filed Jan. 9. 1967 4 Sheets-Sheet 5 INVENTORS, EDWARD EM/L .SCHM/TT ROCCO ALBERT POL/STl/VA ATTORNEY Aug. 26, 1969 E. E. SCHMITT ET AL 3,463,158

POLYGLYCOLIC ACID PROSTHBTIC DEVICES Filed Jan. 9, 1967 4 Sheets-Sheet 4 HEART -5 TISSUE EDWARD EM/L SCHM/TT ROCCO ALBERT POL/ST/NA .1 g ZE INVENTORS.

WMM

ATTORNEY United States Patent us. (:1. 128-334 8 Claims ABSTRACT OF THE DISCLOSURE Polyhydroxyacetic ester, also called polyglycolic acid (PGA), has surgically useful mechanical properties as a solid prosthesis, such as reinforcing pins, screws, plates, or thin sheets. The polyglycolic acid can form a single or bicomponent fabric, either mixed uniformly, or in discrete areas with non-absorbable fibers. In either form, on implantation, in living mammalian tissue, the polyglycolic acid is absorbed, and replaced by living tissue. Fabric structures of an intermixture of PGA and non-absorable material are particularly useful in tissue repair or replacement so that living tissue mechanically unites about the non-absorbable fiber structure, locking it into place.

CROSS REFERENCES This application is a continuation-in-part of application Ser. No. 320,543, filed Oct. 31, 1963 now US. Patent 3,297,033, Jan. 10, 1967, Surgical Sutures.

Field of invention This invention relates to absorbable surgical elements of polyhydroxyacetic ester hereafter called polyglycolic acid (PGA).

Prior art The use of subrnucosal tissue and ribbons therefrom internally is described in such patents as United States Patent 2,167,251, Rogers, Surgical Tape of Sumucosa Tissue, July 25, 1939, United States Patent 2,143,910, Didusch, Ribbon Gut and Method of Using the Same, an. 17, 1939, and United States Patent 2,127,903, Bowen, Tube for Surgical Purposes and Methods of Preparing and Using the Same, Aug. 23, 1938.

U.S.P. 2,836,181, I. S. Tapp, Flexible Nylon Tube and Method for Preparing Same shows a braided heat crimped formic acid treated nylon tube spliced into a blood vessel, with the crimp permitting a desired degree of flexibility.

U.S.P. 3,099,016, M. L. Edwards, Heart Valve shows a plastic cardiac valve, in which a fabric is emplaced in a ring around the valve, and sutured to the heart tissue, to permit the heart tissue to grow to such fabric, and hold the valve in position in the heart.

U.S.P. 3,054,406, F. C. Usher, Surgical Mesh, Sept. 18, 1962, shows the use of a polyethylene woven mesh fabric implanted in the human abdominal wall for reinforcing and healing defects.

U.S.P. 3,108,357, W. J. Liebig, Compound Absorbable Prosthetic Implants, Fabrics and Yarns Therefor shows flexible fabrics of mixed absorbable and non-absorbable textile fibers for implantation, and reinforcement of tissue.

U.S.P. 3,124,136, F. C. Usher, Method of Repairing Body Tissue, Mar. 10, 1964, shows the use of knitted linear polyethylene mesh attached to each side of a tissue defect. The polyethylene is non-absorbable and permanently reinforces the tissue at the site of the defect. Additional details appear in Usher, Ochsner and Tuttle Use of Marlex Mesh in the Repair of Incisional Hernias, The American Surgeon 24, 116-121 (December 1958).

U.S.P. 3,155,095, A. M. Brown Anastomosis Method and Means shows an internal and external asorbable coupling for the joining of vascular vessels.

United States Patents 3,272,204, Absorbable Collagen Prosthetic Implant With Non-Absorbable Reinforcing Strands, Artandi and Bechtol, Sept. 13, 1966, 3,284,557, Process For Crimping An Artificial Implant For Use In An Animal Body," Seymour Polansky, Nov. 8, 1966, and 3,276,448, Collagen Coated Fabric Prosthesis, Richard L. Kronethal, Oct. 4, 1966, each disclose collagen in combination with non-absorbable fibers as surgical prostheses.

SUMMARY Definitions in the textile trades are frequently somewhat ambiguous. For purposes of the present application, certain terms are defined:

A filament is a single, long, thin flexible structure of a non-absorable or absorbable material. It may be continuous or staple.

Staple is used to designate a group of shorter filaments which are usually twisted together to form a long, continuous thread.

Non-absorbable surgically acceptable filaments include filaments of polyalkylenes, such as polyethylene, preferably linear polyethylene with a density of about 0.94 or higher, or polypropylene, preferably isotactic polypropylene; or a polyamide, such as nylon; or a polyester, such as Dacron; or a polyacrylonitrile, such as Orlon or Creslan; or a halogenated polyalkylene, such as polytetrafluorethylene, such as Teflon, or other halogenated polyalkylene, such as Kel-F or FEP; or cotton, or silk, or linen; or a metal such as stainless steel, tantalum, silver, gold, or platinum. The above are illustrative. Any non-absorbable material which is essentially inert in living mammalian tissue, particularly human tissue, is usable as a non-absorbable filament. Those materials having a comparatively high tensile strength and flexibility are preferred.

An absorbable filament is one which is absorbed, that is digested or dissolved, in living mammalian tissue.

A thread is a plurality of filaments, either continuous or staple, twisted together.

A strand is a plurality of filaments or threads twisted, plaited, braided, or laid parallel to form a unit for further construction into a fabric, or used per se, or a monofilament of such size as to be Woven or used independently.

A bi-component filament is a filament composed of two separate materials. As used herein, the term is limited to a filament having one non-absorbable component and one absorbable component. The components may be adjacent. The most easily formed and preferred bi-component filament is a sheathed filament with an internal nonabsorbable material coated, or sheathed, approximately concentrically, with an absorbable component.

A bi-component thread includes a thread of bi-component filaments or a blend of different separate monofilament components twisted together, or both.

A bi-component strand is a strand of one or more bicomponent filaments, or two different filament materials, or both, at least one component of which is absorbable.

A bi-component fabric is a woven, knitted, felted, adhesively united, or otherwise formed fabric of at least two dimensions, or fabric tube having separate strands of bicomponent materials or strands of two separate components, at least one component of which is absorbable.

A coated fabric is a fabric which is coated with a substantially continuous sheet of a second material, as for example by hot melt coating, or coating from a solvent system, or with coating rolls, the base fabric of which may be wholly nonabsorbable, although it may contain an absorbable component. For the present invention, only a living tissue absorbable coating of PGA is considered as the coating layer.

A solid prosthetic device is a thin solid sheet, or plate, or tube, which may be split, or bar, or nail, or screw, or pin or other solid shape which has inherent mechanical strength to act as a solid discrete surgical reinforcing element, and has at least one dimension greater than 2 millimeters, and which may have a dimension as great as about 200 millimeters, or as required, to furnish mechanical support and reinforcement to a bone, or bones, or gland, or organ, for support during a healing process.

The support may be in par-t directive of growth, as for example in nerve tissue, which grows slowly, and as a result has regeneration impaired by the more rapid growth of scar tissue which can block the growth of the nerve tissue. With a wrap-around sheath of PGA sheet, or a split or solid tube used to support, place, hold and protect; regeneration of nerve tissue and function is greatly aided. Other factors may inhibit regeneration of nerve tissue or function, but with the exclusion of scar tissue, such other factors may be separately treated; PGA is particularly useful in splicing nerves because'PGA is completely dissolved in tissue and leaves minimal or no residual scar tissue from the PGA.

A graded transition section is a portion of bi-component fabric, or bi-component strand, which by selection of strands for the fabric, or components for the strand or strands, has a changing composition, over a short distance, of 1 mm. to 15 mm. or more, so that a fabric or strand changes in composition from non-absorbable material, or substantially non-absorbable material, to predominantly or completely absorbable material, whereby living tissue can replace the absorbable component and a gradual transition accomplished between the nonabsorbable reinforcing prosthesis and the adjacent living tissue. With an arterial implant, for instance, a past cause of trouble has been the line of juncture between the implant and the natural artery wall. With a gradual transition, no sharp line of demarkation exists, and hence, failures between the prosthesis and tissue are minimized. With implants of the types shown by Usher, supra, the edges of the reinforcing element could cause difficulties. With a gradual transition, a line of potential risk is eliminated.

For different purposes and in different types of tissue the rate of absorption may vary but in general an absorbable prosthesis should have as high a portion of its original strength as possible for at least three days, and sometimes as much as fifteen days or more, and preferably should be completely absorbed by muscular tissue within from fortyfive to ninety days or more depending on the mass of the cross-section. The rate of absorption in other tissues may vary even more.

In commo with many biological systems, the requirements are not absolute and the rate of absorption as well as the short-term strength requirement varies from patient to patient and at different locations within the body, as well as with the thickness of the section of PGA.

The PGA maybe formed as tubes or sheets for surgical repair and may also be spun as thin filaments and woven or felted to form absorbable sponges or absorbable gauze, or used in conjunction with other structures as prosthetic devices, within the body of a human or animal where it is desirable that the structure have short-term strength, but be absorbable. The useful embodiments include tubes, including branched tubes or Ts, for artery, vein or intestinal repair, nerve splacing, tendon splicing, sheets for tying up and supporting damaged kidney, liver and other intestinal organs, protecting damaged surface areas such as abrasions, particularly major abrasions, or areas where the skin and underlying tissues are damaged or surgically removed.

The synthetic character and hence predictable formability and consistency in characteristics obtainable from a controlled process are highly desirable.

The most convenient method of sterilizing PGA prostheses is by heat under such conditions that any microorganisms or deleterious materials are rendered inactive. A second common method is to sterilize using a gaseous sterilizing agent such as ethylene oxide. Other methods of sterilizing include radiation by X-rays, gamma rays, neutrons, electrons, etc., or high intensity ultrasonic vibrational energy or combinations of these methods. The present materials have such physical characteristics that they may be sterilized by any of these methods.

PGA can be considered as essentially a product of polymerization of glycolic acid, that is hydroxyacetic acid, which in simplified form is shown by the equation:

Preferably n is such that the molecular weight is in the range of 10,000 or more. Above 500,00 the polymer is difficult to mold.

In these molecular weight ranges the polymer has a melt viscosity at 245 C. of between about 400 and about 27,000 poises. Because the PGA is from a synthetic and controllable source, with a controlled molecular weight and controlled small percentage of comonomer, the abisiorbability, stiffness, and other characteristics can be modi- Among several methods by which PGA can be prepared, one preferred route involves the polymerization of glycolide,

the cyclic dimeric condensation product formed by dehydrating hydroxyacetic acid. During polymerization of glycolide, the ring is broken and straight-chain polymerization occurs.

Small quantities of other materials may be present in the chain, as for example, de-lactic acid, its optically active forms, homologs, and analogs. In general, plasticizers tend to interfere with crystallinity, orientation, etc. and weaken fibers, but are useful for sponges and films. Other substances may be present, such as dyes, antibiotics, antiseptics, anaesthetics, and antioxidants. The surfaces of the fabric can 'be coated with a silicone, beeswax, and the like to modify the handling or absorption rate.

The polymerization of glycolide occcurs by heating with or without a catalyst, or may be induced by radiation such as X-rays, gamma rays, electron beams, etc. Polymers may also be obtained by condensing glycolic acid or chloroacetic acid with or without a catalyst under a variety of conditions. Good moldable objects or fibers are most readily obtained when the melt viscosity at 245 C. is about 400 to about 27,000 poises.

Polyhydroxyacetic esters have been described in United States Patent 2,668,162, Lowe, Preparation of High Molecular Weight Polyhydroxyacetic Ester, and United States Patent 2,676,945, Higgins, Condensation Polymers of Hydroxyacetic Acid.

The processes described in the above two patents can be used for producing PGA from which prostheses may be made. Additives such as triphenylphosphite or Santo- Nox, a disulfide aromatic phenol, can be added as color stabilizers.

DRAWINGS FIGURE 1 shows a cross section of a bi-component filament of about 25 percent non-absorbable material coated with about 75 percent absorbable polymer.

FIGURE 2 shows a cross section of a bi-component filament of about 50 percent non-absorbable material coated with about 50 percent absorbable polymer.

FIGURE 3 shows a cross section of a bi-component filament with about 75 percent non-absorbable material coated with about 25 percent absorbable polymer.

FIGURE 4 shows a fiber of a non-absorbable filament.

FIGURE 5 shows a cross section of a polyfilamentary strand of 3 nou-a'bsorbable filaments and absorbable filaments.

FIGURE 6 shows a cross section of a polyfilamentary strand with 6 non-absorbable filaments and 7 absorbable filaments.

FIGURE 7 shows a crosssection of a polyfilamentary strand with 4 absorbable filaments and 9 non-absorbable filaments. I

FIGURE 8 shows a woven fabric the central portion of non-absorbable strands graded in both warp and woof into a 75 percent non-absorbable, then 50 percent nonabsorbable, then 25 percent non-absorbable strands.

FIGURE 9 shows a knitted fabric graded from a 100 percent non-absorbable strand through a 75 percent nona-bsorbable strand, then a 50 percent non-absorbable strand, to a 25 percent non-absorbable strand.

FIGURE 10 shows a spliced artery having an internal sleeve with slightly tapered ends, with a sewn splice.

FIGURE 11 is a cross section of a spliced artery having an internal sleeve with expanded ends.

FIGURE 12 shows a prosthetic sleeve formed of a unitary coupling of solid polyglycolic acid with slightly expanding ends to aid in holding a blood vessel about the sleeve. I 9

FIGURE 13 shows the sleeve of FIGURE 12 in use in which an external spring clip of solid polyglycolic acid holds the ends of the blood vessel together.

FIGURE 14 shows the sleeve of FIGURE 12 in which two expandable annular clips are used to hold the ends of the blood vessel approximated.

FIGURE 15 is a portion of a woven tube of certain individual strands which are at least in part absorbable.

FIGURE 16 shows a portion of a heart valve emplaced in heart tissue using a fabric in part composed of polyglycolic acid to aid in holding the valve in place.

FIGURE 17 shows a broken bone, the ends of which are held together by a solid bar of polyglycolic acid held to the bone by polyglycolic acid screws.

FIGURE 18 shows a broken bone, the ends of which are held in position by an internal fluted pin of polyglycolic acid.

PGA for the construction of the prostheses shown in the drawings can be produced as set forth in the following examples, in which parts are by weight, unless otherwise clearly indicated:

EXAMPLE 1 100 parts of recrystallized glycolide (melting point 85.0 to 85.5 C.) are intimately mixed with 0.02 part of methoxyacetic acid, 0.03 part of phenoldisulfide (Santo- Nox), and 0.03 part antimony trifiuoride. Separate glass tubes are each charged with approximately 20 grams of the mixture, deoxygenated by repeated evacuation and argon purging, then sealed under vacuum and heated to 185 to 190 C. for 4 /2 hours. On cooling a white opaque tough PGA is produced in a 97.5% yield with a melt viscosity at 245 C. of 5,000 poises. The polymer is reheated and spun into filaments at a temperature of about 230 C. at a speed of about 150 feet per minute. The filaments produced are cooled, then drawn at about 55 C. When drawn to five times the original length a strong tough filament is produced. The dry filaments are in condition for use.

EXAMPLE 2 The polymer of the preceding example is formed into a plurality of smaller filaments, seven of which are twisted into a polyfilamentary strand, which is sterilized and used following the techniques of Example 1.

Because it is a synthetic polymer the methods of forming are more versatile than in starting with naturally occurring materials.

6 EXAMPLE 3 Into a suitable reaction vessel there is charged 400 parts of a commercial glycolic acid which is then heated from room temperature to about 200 C. over a period of about four hours. When the pot temperature has reached 185 C., the pressure of the system is reduced from atmospheric pressure to 15 mm. of Hg, causing the water of condensation and/or esterification to distill off. The residue is allowed to cool and is pulverized into about 280 parts of a powder which is then added in small increments to a suitable pyrolysis chamber maintained at a temperature of about 250-280 C. at a pressure of less than 15 mm. of Hg. The distillate which weighed about 238 parts is dissolved in a minimum amount of hot ethyl acetate, and after decolorizing and purifying with active carbon, the distillate is recrystallized from the above solution to provide 160 parts of product having a melting point of about 82.5-84.0 C. The infrared spectrum confirms that the product is substantially pure glycolide.

The glycolide thus prepared is polymerized in the presence of an alcohol free of non-benzenoid unsatura tion and free of any reactive groups other than alcoholic hvdroxy groups and in the presence of SnCl -2H O.

Into a heavy walled glass tube having a bore of about and sealed at one end is charged with 3 parts of the substantially pure glycolide composition, 0.04 part of a 0.1% ether solution of SnCl -2H O (about 0.0013% of SnCl -2H Q based on the weight of the substantially pure glycolide composition), 0.0166 part of lauryl alcohol (0.346 mole percent based on the moles of the substantially pure glycolide composition), and a magnetic steel ball 2 in diameter. The tube is evacuated and purged with argon. The tube is evacuated again to a vacuum of less than 1 mm. of Hg and the top is sealed. The reaction tube is. placed in a vertical position in a closed glass chamber throughout which dimethyl phthalate is refluxed at 222 C. The boiling point of the dimethyl phthalate is controlled by decreasing the pressure of the system. At periodic intervals after melting, the viscosity of the reaction mixture is measured by raising the steel ball by means of a magnet and measuring the rate of the fall of the ball in sec./in. Ninety minutes after the melt is first achieved, the ball drop time is 550 sec./in. or about 7200 poises, and after minutes, the ball drop time is 580 sec./in. or about 7600 poises.

The PGA thus produced is spun into .002 inch diameter fibers and used to form bi-component strands.

Additional PGA, similarly produced is used to coat Dacron filaments, in varying weight ratios to form bi-component strands which are braided into tubular arterial implants to splice into sections of arteries.

Additional PGA, similarly produced is used to form sheets. These sheets are wrapped around nerves, traumatically severed, to protect such nerves from invasive scar tissue growth, while the nerve is regenerating.

Also the PGA so produced is fabricated into the prosthetic devices shown in the drawings.

As is shown in the drawings, a bi-component filament 23 was formed by dipping a non-absorbable filament 21 of Dacron into a PGA melt forming a PGA coating 22 on the surface of the non-absorbable Dacron 21.

As shown in FIGURE 1 the dip was such that approximately 25% of the cross section was of Dacron and 75% of PGA.

In FIGURE 2 the structure is the same except that the relative proportions are changed to approximately 50% of each material.

In FIGURE 3 the structure is the same except that the proportions are changed such that approximately 75% of the cross section is of Dacron and about 25% on the surface is of PGA.

In FIGURE 4 a Dacron monofilament is shown.

In FIGURE 5 is shown a cross section of a bi-component thread. The bi-component thread consists of 3 nonabsorbable filaments 25 of Dacron and 10 absorbable filaments 24 of PGA.

FIGURE 6 is a similar bi-component thread except that the composition is changed to 6 non-absorbable filaments and 7 PGA filaments.

FIGURE 7 shows a cross section of a bi-component thread having 9 non-absorbable Dacron filaments, and 4 PGA filaments.

It is to be understood that in surgical use the ratios shown are not critical but are representative. In forming a graded transition section, either the bi-component filaments or the bi-component threads may change by discrete increments or gradually from a completely non-absorbable material to the completely absorbable PGA. The size of bicomponent filaments and the size of bi-component threads are a matter of choice depending upon the location in which the resultant prosthetic device is to be used.

FIGURE 8 shows a woven fabric in which each of the warp and the woof are constructed, starting in the center, with a 100% non-absorbable material 33, such as Dacron, and changing by 25% increments in discrete zones 34, until the outer set of threads 36 in each direction is 25 non-absorbable and 75% PGA.

Such a construction permits the use of Dacron or linear polyethylene or isotactic polypropylene in the construction of a repair patch, such as shown in Usher, supra, but in which gradation from the fully reinforcing, non-absorbable material to absorbable material is gradual. The spacing between the threads in the fabric can be chosen for a particular application. Usually, if the prosthetic device is to be used for the repair of hernias, a comparatively widely spaced weave is desired. If used for an area in which liquid retention is critical, such as an artery or vein, the weave is much closer.

In FIGURE 9 is shown a knitted fabric 27, in which the respective strands are 100% non-absorbable 28, followed by two rows of 75 non-absorbable 25 PGA 29 followed by two rows of 50% non-absorbable 50% PGA 30, followed by two rows of 25 non-absorbable 75% PGA 31.

In such a graded construction, the rate of change with distance or the number of rows of a particular composition are adjusted to fit the desired use. For smaller patches the width of each proportion of components is smaller than for large potches.

In FIGURE 10 is shown an artery 37 which is joined together over a tapered end PGA tube 38 which forms a stent about which the ends of the artery wall are joined by a suture splice 39. The tapered end is easier to insert in the artery.

In FIGURE 11 the artery walls 40 are joined together over a flared end PGA tube 41 and the ends are joined by a suture splice 42.

FIGURE 12 shows the flared end PGA tube 41.

In FIGURE 13 is shown a blood vessel 43, the ends of which are each separately placed over the end of a flared PGA tube and which blood vessel is held in place with the ends adjacent to permit healing by a PGA spring clip 44. PGA, such as produced in the above Example 3, shows an Izod impact strength of 0.14 ft. lb. per inch width or greater. It may be heated and formed into a desired shape which shape is retained on cooling, and by shaping as a flat spring clip, can be used to hold together the walls of a blood vessel 43 until natural regeneration takes place.

In FIGURE 14 is shown a similar splice of a blood vessel 45 but in which the ends are held together by an annular clip 46 of molded PGA. Such annular clips are well known for the attachment of radiator hoses to radiators in automobiles and the attachment of other flexible tubing to connectors. By a suitable choice of diameter and shape, as is well known in the industry, the radial compression at all points about the periphery may be caused to be approximately uniform and within a desired range. This is important in the splicing of blood vessels as it is desired to hold the blood vessel in position during regeneration, but yet not hold the vessels so tightly that necrosis sets in because of an impaired blood supply to the vessel walls.

FIGURE 15 shows a section of a woven tube having bi-component strands 48 in the periphery. Such a woven tube is conveniently used as a prosthetic device. Tapp, supra, shOWS a nylon tube for such purpose. By incorporating PGA containing strands into the ends of such a prosthetic device, the union of the natural artery to the artificial artery is much stronger because there is not a sharp line of demarkation.

FIGURE 16 shows a heart valve 49 such as shown by Edwards, supra, with a bi-component fabric 50 surrounding the heart valve and sewn into the heart tissue 51. By suturing the heart tissue to a bi-component fabric, as the PGA portion of the fabric is absorbed, the heart tissue grows into the remaining non-absorbable structure and forms a more secure union.

FIGURE 17 shows a broken bone 52 joined by a PGA splice bar 53 which is held to the bone by PGA screws 54.

FIGURE 18 shows a different type of splice for a broken bone in which a broken bone 55 is jointed by a PGA fluted pin 57 inserted into the bone marrow 56. The pin is chosen of such size and shape as to fill the hollow in the bone and give mechanical strength and prevent motion at the break.

Absorbable splices or bone pins hold the bone in place until it has an opportunity to knit and then gradually dissolve. In the past, metallic reinforcing elements have frequently been used. Such metallic elements add weight to the body, and perhaps cause inflammation by their physical presence, or must be removed at a separate subsequent operation. Additionally, if a bone pin is used internally of a bone, the volume of bone marrow is markedly reduced. When the PGA bone pin dissolves, no scar tissue remains and bone marrow is regenerated through the bone permitting the bone marrow to accomplish its organic functions.

The drawings above are illustrative only, of embodiment of the present invention in which vario s prosthetic devices are incorporated into the human Eddy to aid impaired functions of. natural elements:-'- rom the above drawings and descriptions, it will hes yious to those skilled in the art that many other modi cations 'may be adapted for particular injuries or ills to which the flesh is heir.

The finding that polyglycolic acid, abbreviated PGA, is absorbable in living tissue, and has marked mechanical strength, as a fiber or solid, including sheet, and hence can be used as an element in, or as, a surgical prosthesis, is most unexpected and unpredictable.

Catgut, or regenerated collagen has in the past been used for tissue emplacement, but with collagen, as the collagen is absorbed, a fibrotic tract replaces the collagen, so that in efiect scar tissue remains at the site of the emplanted collagen for many years, in many instances for life. Some patients are allergic to collagen. PGA is not a protein, has no amino acids, and has given no evidence of allergic reactions in thousands of implants. With the present PGA prostheses, the PGA is completely absorbed, and a minimal or no trace of the inserted matter remains after a comparatively short period. This complete absorption, without residual fibrotic tissue, is unique, and an important contribution to surgery.

As it is obvious that examination of such prosthetic devices in humans must wait until autopsy, after death from natural causes, experimental results were conducted on laboratory animals which would permit sacrifice and examination at selected periods. These are shown in the following examples:

EXAMPLE 4 Absorbable intermedullary rod Longitudinal incisions were made on the superior surface of the hind legs of anesthetized rabbits to expose the upper end of the femur, close to the point of attachment to the hip. At a point about 1" from the neck portion, the shaft of the femur was out completely through by means of a small circular saw attached to an air drill. A hole about A; inch in diameter was drilled through the bony process known as the greater trochanter vertically into the narrow cavity of the shaft portion of the femur. The cut ends of the femur shaft were approximated and while they were held firmly in place a medullary rod of polyglycolic acid about two inches in length and about inch in diameter was driven through the hole in the trochanter into the marrow cavity past the point at which the shaft of the femur had been parted. The effect of the medullary rod was to hold the cut ends of the femur shaft firmly in place. The top end of the medullary pin was flush with the surface of the trochanter.

The parted soft tissues were approximated with sutures, the injured legs were splinted with wooden tongue depressors affixed to the leg with adhesive tape and the animals were returned to their cages. X-rays were taken of the injured legs at weekly intervals and the progress of new bone formation was observed. Animals were sacrificed at the end of 6, l2, l8, and 24- weeks and the femurs which had been operated upon were dissected out and examined. These femurs were compared with similarly resected femurs which had been repaired with Type 316 stainless steel pins'of equivalent size to those made of PGA.

With both the experimental and control animals the course of healing was uneventful. The breaks were essentially healed by the 6th week. After sacrifice the femurs were split longitudinally and the effect of time on the implants were observed. As expected in the relatively short times used the stainless steel pin was essentially inert but since the internal space was largely occluded, where the metallic pin was present, there was no marrow tissue.

Where the medullary rod of polyglycolic acid had been used, at six weeks the overall structure of the rod was essentially unchanged but there were fissures developing on the surface and the cut ends which had been sharply defined were somewhat rounded. The rod was somewhat softened on thesurface. There was a progressive increase in the amount of erosion of the PGA rod with time but this erosion was never associated with inflammation or other adverse reactors. By the 24th week the rod of polyglycolic acid was essentially digested and the bone now showed normal tissue architecture.

EXAMPLE 5 Absorbable bone plate affixed with absorbable pins Femurs of the hind legs of rabbits were bisected as described in Example 4. The cut ends were reapproximated and immobilized by use of an internal support made from a sheet of polyglycolic acid approximately inch thick 4" wide and 1 inch long, shaped to conform generally to the bone by softening the plastic with heat and premolding it about a metal rod of suitable diameter. The premolded plate was centrally located over the cut bone and while held in position, small holes were drilled through the plate and completely through the bone with a inch drill, two holes on each side of the bone break. Small PGA nails about inch long and slightly over A inch in diameter made by flattening rod of this diameter by pressing against a heated surface were driven through the holes in the PGA plate and completely through the bone to hold the plate in place. The soft tissue was reapproximated, the broken legs splinted and the animals were returned to their cages. X-rays were taken weekly and animals were sacrificed at 3, 6, 12, 18 and 24 week intervals. The legs which had been operated upon were carefully dissected to determine the fate of the polyglycolic acid implant and to observe the course of healing. At 3 weeks the bone was partially knit and the PGA implant was essentially intact. By 6 weeks the break in the bone was healed and the PGA plate was showing signs of erosion. The nails also showed signs of breakdown, and the plate could be moved in relation to the bone. By the 12th week the nails were so weakened and the holes in the PGA plate so enlarged that the remains of the plate could be easily separated from the bone. By the 24th week the plate was almost completely absorbed,

, the bone was covered by the normal periosteal membrane and where absorption was complete there was nothing to indicate that the PGA had ever been present.

EXAMPLE 6 Arterial prosthesis made of a mixture of polyester and polyglycolic acid fibers Yarn containing a mixture of polyglycolic acid monofilaments and polyester (polymer of ethylene glycol and terephthalic acid) monofilaments was made by combining sufficient monofilaments of PGA with a polyester yarn to make about 25% of the weight of the yarn polyglycolic acid. This yarn was converted into a tightly woven cloth which was in turn formed into a tube by wrapping cut pieces of suitable size about a mandrel and sewing together the open sides with polyester thread.

In this example where the arterial prostheses were to be used in rabbits, the tubes were only V in diameter.

The abdominal aorta was exposed by incision through the ventral wall; two clamps separated by about 1 /2 inches were placed on the abdominal aorta just distal to the renal artery. The approximately 1 inch of the abdorni nal aorta between the clamps was resected and a comparable length of prosthetic tubing made as described above was sewn in place. The clamps were removed, and the animal was observed closely until blood seepage had stopped. The abdomen was then closed and the animal returned to its cage. Sacrifices were made at the end of 1, 3, 6, l2, and 18 weeks and the prosthetic implant and the neighboring tissue was examined. After the first week there was little change in the prosthesis. The pores of the fiber were closed with fibrin and some new cell growth was noticeable at the cut ends of the blood vessel. By three weeks the fibrin clots had been partially replaced by new cells which represented the partial development of a pseudo intimal lining extending from the ends of the original vessel. The polyglycolic acid filaments were still intact but were showing indications of surface erosion on microscopic examination. By 6 weeks the pseudo intimal lining was complete. Blood vessels were beginning to develop in this tissue layer. Growth of cells was occurring through the pores of the prosthesis which were now substantially enlarged by the obvious diminution in size of the PGA filaments which were no longer continuous. Shredding of the PGA filaments was evident but the complete development of the pseudo intima prevented the shreds from entering the blood stream where they could represent foci for clot formation. By the twelfth week the PGA was essentially replaced by tissue elements which formed a well vascularized multicellular layer completely capturing the polyester filaments of the prosthesis. The picture at 18 weeks was similar to that at 12 weeks with more vascularization and greater organization of the cells of the inner lining and outer surface of the prosthesis. There was a conspicuous absence of any inflammatory response of abnormal tissue reaction. The absorption of the polyglycolic acid gave sufficient space in the fiber network to permit adequate cell growth and proper vascularization so that necrosis of tissue did not develop.

So far as inspection permits, similar results appear to be obtained in humans. Of course with humans, and larger animals proportionately sized prostheses must be used.

We claim:

1. A surgical prosthesis comprising non-absorable filaments shaped as a living tissue reinforcing element, and mixed with an coacting with said non-absorable filaments, in at least a part of the element, a structure consisting essentially of polyglycolic acid, whereby on implantation in living tissue, the polyglycolic acid structure is absorbed by the living tissue which replaces the polyglycolic acid and interlocks with the non-absorable filaments, said prosthesis being sterile at time of implantation.

2. The prosthesis of claim 1 in which the reinforcing element comprises a non-absorbable strand fabric mesh section, and interwoven and graded thereinto, bi-component strands in a graded transition portion, the individual strands of which are of proportionately increasing polyglycolic acid composition and decreasing non-absorb able filament composition, at increasing distances from said non-absorable strand fabric mesh section.

3. The fabric of claim 2 in which individual strands are composed of a plurality of non-absorbable filaments and polyglycolic acid filaments with the proportionate number of polyglycolic acid filaments increasing away from the non-absorbable fabric section.

4.. The surgical fabric of claim 2 in which the bicomponent strands consist of at least one bi-component filament, with the relative polyglycolic acid proportion increasing away from the non-absorbable portion.

5. The surgical prosthesis of claim 1 in which the non-absorbable reinforcing element is a tubular fabric graft with a graded transition from a section of nonabsorable strands to a section in which at least a pre- 12 dominant portion, by weight, of the strands consist of polyglycolic acid.

6. The surgical prosthesis of claim 1 in which the non-absorable filaments are coated with a substantially continuous layer of polyglycolic acid.

7. A bi-component strand for the fabrication or attachment of a surgical prosthesis comprising at least one filament of a non-absorbable material and united therewith polyglycolic acid.

8. The bi-component strand of claim 7 in which each filament of non-absorable material is coated, approximately concentrically, with polyglycolic acid.

References Cited UNITED STATES PATENTS 3,272,204 9/1966 Artandi et al 128-334 3,276,448 10/1966 Kronenthal 128-334 3,297,033 1/1967 Schmitt et a1. 128-3355 3,304,557 2/1967 Polansky 128-334 3,316,557 5/1967 Liebig 128-334 DALTON L. TRULUCK, Primary Examiner US. Cl. X.R. 3-1

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent NO. 3 ,463,l58 August 26, 1969 Edward Emil Schmitt et a1.

It is certified that error appears in the above identified patent and that said Letters Patent are hereby corrected as shown below:

Column 1, line 40, "Sumucosa" should read Submucosa Column 2, line 2, "asorbable" should read absorbable Column 3, line 67, "splacing" should read splicing Column 4, line 40, "de-lactic" should read d,l-lactic Column 6, line 12, "250-280 C." should read 2S0-285 C. Column 7, line 46, "patches" should read patches Column 10, line 72, "an" should read and Signed and sealed this 4th day of August 1970.

(SEAL) Attest:

Edward M. Fletcher, Jr.

Attesting Officer Commissioner of Patents WILLIAM E. SCHUYLER, IR.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US3272204 *22 sept. 196513 sept. 1966Ethicon IncAbsorbable collagen prosthetic implant with non-absorbable reinforcing strands
US3276448 *14 déc. 19624 oct. 1966Ethicon IncCollagen coated fabric prosthesis
US3297033 *31 oct. 196310 janv. 1967American Cyanamid CoSurgical sutures
US3304557 *28 sept. 196521 févr. 1967Ethicon IncSurgical prosthesis
US3316557 *15 févr. 19652 mai 1967Meadox Medicals IncSurgical, vascular prosthesis formed of composite yarns containing both synthetic and animal derivative strands
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3620218 *25 août 196916 nov. 1971American Cyanamid CoCylindrical prosthetic devices of polyglycolic acid
US3849805 *1 nov. 197226 nov. 1974Attending Staff Ass Los AngeleBone induction in an alloplastic tray
US3878565 *25 juil. 197322 avr. 1975Providence HospitalVascular prosthesis with external pile surface
US3883901 *27 nov. 197320 mai 1975Rhone Poulenc SaMethod of replacing or repairing the body with bioresorbable surgical articles
US3908201 *8 juin 197330 sept. 1975Ici LtdProsthetics
US3996623 *30 juin 197514 déc. 1976Kaster Robert LMethod of implanting a prosthetic device and suturing member therefor
US4032993 *25 juin 19755 juil. 1977Rhone-Poulenc IndustriesCopolyester of succinic and oxalic acids, sutures
US4042978 *11 juin 197523 août 1977Imperial Chemical Industries LimitedProsthetics
US4127902 *17 mars 19785 déc. 1978Homsy Charles AStructure suitable for in vivo implantation
US4128612 *3 nov. 19755 déc. 1978American Cyanamid CompanyMaking absorbable surgical felt
US4181983 *29 août 19778 janv. 1980Kulkarni R KAssimilable hydrophilic prosthesis
US4243775 *13 nov. 19786 janv. 1981American Cyanamid CompanySynthetic polyester surgical articles
US4275813 *4 juin 197930 juin 1981United States Surgical CorporationCoherent surgical staple array
US4279249 *17 oct. 197921 juil. 1981Agence Nationale De Valorisation De La Recherche (Anvar)New prosthesis parts, their preparation and their application
US4329743 *27 avr. 197918 mai 1982College Of Medicine And Dentistry Of New JerseyPolylactic acid for surgical implant
US4338926 *21 nov. 198013 juil. 1982Howmedica, Inc.Bone fracture prosthesis with controlled stiffness
US4365357 *25 avr. 198028 déc. 1982Merck Patent Gesellschaft Mit Beschrankter HaftungSurgical network and a prepolymer and monomer
US4379138 *28 déc. 19815 avr. 1983Research Triangle InstituteBiodegradable polymers of lactones
US4411027 *23 févr. 198225 oct. 1983University Of Medicine And Dentistry Of New JerseyBio-absorbable composite tissue scaffold
US4416028 *4 juin 198022 nov. 1983Ingvar ErikssonBlood vessel prosthesis
US4439391 *7 janv. 198127 mars 1984International Paper CompanyFabric texture, encasing, curing, leaching
US4441215 *23 févr. 198310 avr. 1984Kaster Robert LVascular graft
US4457028 *14 oct. 19823 juil. 1984Merck Patent Gesellschaft Mit Beschrankter HaftungSurgical materials suitable for use with bone cements
US4467478 *20 sept. 198228 août 1984Jurgutis John AHuman ligament replacement
US4481353 *7 oct. 19836 nov. 1984The Children's Medical Center CorporationBioresorbable polyesters and polyester composites
US4495664 *28 juil. 198229 janv. 1985CeraverTitanium or titanium alloy pin for cement-free fixing in a long bone to form a prosthesis
US4501029 *13 avr. 198326 févr. 1985Mcminn Derek J WDevice for assisting in repair of a severed tendon
US4512038 *6 avr. 198123 avr. 1985University Of Medicine And Dentistry Of New JerseyCarbon fiber, polylactic acid composites, fractured bones
US4522593 *7 juil. 198311 juin 1985Fischer Dan EKnitted gingival retraction cord
US4523591 *22 oct. 198218 juin 1985Kaplan Donald SPolymers for injection molding of absorbable surgical devices
US4560374 *17 oct. 198324 déc. 1985Hammerslag Julius GMethod for repairing stenotic vessels
US4584722 *10 mai 198329 avr. 1986Yeda Research And Development Co., Ltd.Pet core embedded in silicone rubber with biodegbadable polyglycolic acid sleeve
US4585458 *18 août 198329 avr. 1986Kurland Kenneth ZMeans and method of implanting bioprosthetics
US4594407 *20 sept. 198310 juin 1986Allied CorporationPolyester coating
US4633873 *26 avr. 19846 janv. 1987American Cyanamid CompanySurgical repair mesh
US4650851 *19 mars 198617 mars 1987Pfizer Hospital Products Group, Inc.Purification of glycolide
US4652264 *25 avr. 198524 mars 1987American Cyanamid CompanyProsthetic tubular article
US4744365 *22 sept. 198717 mai 1988United States Surgical CorporationTwo-phase compositions for absorbable surgical devices
US4754745 *7 juil. 19865 juil. 1988Horowitz Bruce SConformable sheet material for use in brachytherapy
US4763642 *7 avr. 198616 août 1988Horowitz Bruce SIntracavitational brachytherapy
US4776329 *20 sept. 198511 oct. 1988Richards Medical CompanyFor repairing a bone fracture
US4792336 *3 mars 198620 déc. 1988American Cyanamid CompanyGlycolic acid ester and trimethylene carbonate copolymer
US4804691 *28 août 198714 févr. 1989Richards Medical CompanyMethod for making a biodegradable adhesive for soft living tissue
US4815449 *30 mars 198728 mars 1989Horowitz Bruce SDelivery system for interstitial radiation therapy including substantially non-deflecting elongated member
US4838884 *17 oct. 198613 juin 1989American Cyanamid CompanyBioabsorbable polyglycolic acid
US4840632 *21 mai 198620 juin 1989Kampner Stanley LHip prosthesis
US4843112 *12 mars 198727 juin 1989The Beth Israel Hospital AssociationBioerodable implant composition
US4848367 *18 mars 198818 juil. 1989Odis L. AvantMethod of effecting dorsal vein ligation
US4850999 *26 mai 198125 juil. 1989Institute Fur Textil-Und Faserforschung Of StuttgartFlexible hollow organ
US4870966 *1 févr. 19883 oct. 1989American Cyanamid CompanyBioabsorbable surgical device for treating nerve defects
US4871365 *24 déc. 19863 oct. 1989American Cyanamid CompanyPolyglycolic acid, trimethylene carbonate linkager
US4923470 *22 mars 19888 mai 1990American Cyanamid CompanyProsthetic tubular article made with four chemically distinct fibers
US4942875 *21 janv. 198824 juil. 1990American Cyanamid CompanySurgical repair device having absorbable and nonabsorbable components
US4973333 *10 août 198827 nov. 1990Richards Medical CompanyResorbable compressing screw and method
US4990158 *10 mai 19895 févr. 1991United States Surgical CorporationElastic core and inelastic sheath yarn
US4990161 *6 sept. 19845 févr. 1991Kampner Stanley LAnchor for a bone joint
US4997440 *10 août 19905 mars 1991American Cyanamid CompanyVascular graft with absorbable and nonabsorbable components
US5013315 *12 juil. 19857 mai 1991Minnesota Mining And Manufacturing CompanySemiabsorbable bone plate spacer
US5053035 *24 mai 19901 oct. 1991Mclaren Alexander CFlexible intramedullary fixation rod
US5061281 *17 déc. 198629 oct. 1991Allied-Signal Inc.Bioresorbable polymers and implantation devices thereof
US5085861 *12 mai 19894 févr. 1992The Beth Israel Hospital AssociationBone cement; calcium phosphate in polyester matrix
US5124103 *2 août 199023 juin 1992United States Surgical CorporationGlycolide-rich polymer dispersed in matrix of lactide-rich polymer; nonbrittle, tensile strength, high distortion temperature, hot-wet creep resistance
US5147399 *28 févr. 199115 sept. 1992Dellon Arnold LPromoting regrowth of a severed nerve across a nerve gap
US5147400 *12 sept. 199015 sept. 1992United States Surgical CorporationConnective tissue prosthesis
US5217495 *13 nov. 19908 juin 1993United States Surgical CorporationSynthetic semiabsorbable composite yarn
US5292328 *18 oct. 19918 mars 1994United States Surgical CorporationPolypropylene multifilament warp knitted mesh and its use in surgery
US5314446 *19 févr. 199224 mai 1994Ethicon, Inc.Sterilized heterogeneous braids
US5319038 *9 févr. 19937 juin 1994Johnson & Johnson Orthopaedics, Inc. G35Purification and stabilization of high molecular weight polylactide by grinding, contacting with methanol, filtering, contacting with acetone, filtering, drying, storing in inert atmosphere
US5334216 *10 déc. 19922 août 1994Howmedica Inc.Hemostatic plug
US5350388 *3 juin 199227 sept. 1994Albert Einstein College Of Medicine Of Yeshiva UniversityHemostasis apparatus and method
US5358475 *28 sept. 199225 oct. 1994United States Surgical CorporationHigh molecular weight bioresorbable polymers and implantable devices thereof
US5376118 *26 mars 199327 déc. 1994United States Surgical CorporationSupport material for cell impregnation
US5380329 *28 juil. 199210 janv. 1995Dental Marketing Specialists, Inc.Bone augmentation method and apparatus
US5403346 *31 déc. 19924 avr. 1995Loeser; Edward A.Self-affixing suture assembly
US5403347 *2 mars 19944 avr. 1995United States Surgical CorporationBlock copolymer of glycolic acid with 1,4 dioxane-2-one and 1,3 dioxane-2-one; clips, staples, monofilament sutures, pins, screws, prosthetic devices, anastomosis rings and growth matrices
US5431679 *10 mars 199411 juil. 1995United States Surgical CorporationAbsorbable block copolymers and surgical articles fabricated therefrom
US5458636 *20 juil. 199417 oct. 1995U.S. Biomaterials CorporationProsthetic device for repair and replacement of fibrous connective tissue
US5475063 *14 déc. 199412 déc. 1995United States Surgical CorporationBlends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made
US5489297 *2 nov. 19946 févr. 1996Duran; Carlos M. G.Bioprosthetic heart valve with absorbable stent
US5522841 *29 déc. 19944 juin 1996United States Surgical CorporationHaving blocks of polyalkylene oxide, glycolic acid ester, 1,4-dioxan-2-one randomly polymerized with 1,3-dioxan-2-one
US5522904 *13 oct. 19934 juin 1996Hercules IncorporatedComposite femoral implant having increased neck strength
US5542594 *6 oct. 19936 août 1996United States Surgical CorporationFor driving surgical fasteners into body tissue
US5545212 *21 nov. 199413 août 1996Terumo Kabushiki KaishaArtificial blood vessel
US5554170 *26 janv. 199510 sept. 1996United States Surgical CorporationPolylactone sutures
US5571193 *11 juin 19925 nov. 1996Kampner; Stanley L.Implant with reinforced resorbable stem
US5618313 *11 oct. 19948 avr. 1997United States Surgical CorporationAbsorbable polymer and surgical articles fabricated therefrom
US5628788 *7 nov. 199513 mai 1997Corvita CorporationSelf-expanding endoluminal stent-graft
US5632753 *4 avr. 199527 mai 1997Loeser; Edward A.Surgical procedures
US5681310 *30 oct. 199528 oct. 1997Yuan; Hansen A.Vertebral auxiliary fixation device having holding capability
US5697976 *14 sept. 199416 déc. 1997United States Surgical CorporationBioabsorbable implant material
US5700269 *13 nov. 199523 déc. 1997Corvita CorporationEndoluminal prosthesis deployment device for use with prostheses of variable length and having retraction ability
US5707647 *14 nov. 199613 janv. 1998Atrix Laboratories, Inc.Adjunctive polymer system for use with medical device
US5717030 *6 déc. 199610 févr. 1998Atrix Laboratories, Inc.Adjunctive polymer system for use with medical device
US5733950 *25 sept. 199531 mars 1998Atrix Laboratories, IncorporatedDissolving water insoluble biodegradable thermoplastic polymer in biocompatible water soluble solvent, placing in body, allowing solvent to dissipate or diffuse into body fluid and polymer to coagulate or solidify to form implant
US5739176 *18 mars 199414 avr. 1998Atrix Laboratories, Inc.Dissolving biocompatible water-insoluble biodegradable thermoplastic polymer in water-soluble organic solvent, placing in implant site in body, allowing solvent to diffuse or dissipate into body fluid so polymer coagulates to solid
US5741333 *3 avr. 199621 avr. 1998Corvita CorporationSelf-expanding stent for a medical device to be introduced into a cavity of a body
US5756651 *17 juil. 199626 mai 1998Chronopol, Inc.Impact modified polylactide
US5800510 *6 juin 19951 sept. 1998Meadox Medicals, Inc.Implantable tubular prosthesis
US5849037 *3 avr. 199615 déc. 1998Corvita CorporationSelf-expanding stent for a medical device to be introduced into a cavity of a body, and method for its preparation
US5908427 *30 mai 19971 juin 1999United States Surgical CorporationSurgical stapling apparatus and method
US5908918 *26 mai 19981 juin 1999Chronopol, Inc.Degradable blends containing polylactide, a degradable impact modifier, and a degradable plasticizer for use in packaging films.
US5911753 *24 nov. 199715 juin 1999Meadox Medicals, Inc.The present invention relates to an implantable tubular prosthesis having a textile substrate with a fluid-tight microporous lining.
US5935594 *6 avr. 199810 août 1999Thm Biomedical, Inc.Employing a surfactant for efficiently incorporating a bioactive agent into the interstices of a porous and biodegradable polylactic acid body, wherein the bioactive agent is deposited on the internal surface
US5948020 *26 déc. 19977 sept. 1999Sam Yang Co., Ltd.Implantable bioresorbable membrane and method for the preparation thereof
US5964774 *12 sept. 199712 oct. 1999United States Surgical CorporationSurgical stapling apparatus and method with surgical fabric
US5968091 *26 nov. 199719 oct. 1999Corvita Corp.Stents and stent grafts having enhanced hoop strength and methods of making the same
US5981825 *13 mai 19949 nov. 1999Thm Biomedical, Inc.Device and methods for in vivo culturing of diverse tissue cells
US5990194 *7 nov. 199723 nov. 1999Atrix Laboratories, Inc.Biodegradable in-situ forming implants and methods of producing the same
US5997568 *17 janv. 19977 déc. 1999United States Surgical CorporationAbsorbable polymer blends and surgical articles fabricated therefrom
US6007565 *5 sept. 199728 déc. 1999United States SurgicalAbsorbable block copolymers and surgical articles fabricated therefrom
US6045560 *17 juin 19964 avr. 2000United States Surgical CorporationSurgical stapling apparatus with biocompatible surgical fabric
US6071530 *26 juin 19976 juin 2000Atrix Laboratories, Inc.Dispensing solution of biodegradable, water insoluble, thermoplastic resin with biocompatible solvent onto support; coagulation
US6083524 *6 oct. 19974 juil. 2000Focal, Inc.Polymerizable biodegradable polymers including carbonate or dioxanone linkages
US6099557 *5 févr. 19998 août 2000Meadox Medicals, Inc.Implantable tubular prosthesis
US6136018 *2 août 199924 oct. 2000United States Surgical CorporationAbsorbable block copolymers and surgical articles fabricated therefrom
US6162537 *31 oct. 199719 déc. 2000Solutia Inc.Grafting fibers of polymers
US61770957 janv. 200023 janv. 2001Focal, IncPolymerizable biodegradable polymers including carbonate or dioxanone linkages
US61870087 juil. 199913 févr. 2001Bristol-Myers SquibbDevice for temporarily fixing bones
US619123610 oct. 199720 févr. 2001United States Surgical CorporationCopolymerizing a mixture of 1,4 dioxane-2-one and 1,3 dioxane-2-one to the point where all the 1,3 dioxane-2-one is incorporated in a polymer but residual 1,4-dioxane-2-one monomer remains, adding glycolide, then block copolymerizing
US62069083 mai 199927 mars 2001United States Surgical CorporationAbsorbable polymer and surgical articles fabricated therefrom
US622811127 sept. 19968 mai 2001Bionx Implants OyFirst and second degradation and detaching times over longitudinal axis
US62289541 nov. 19948 mai 2001United States Surgical CorporationImpact resistance and improved cyclic flex
US623746030 avr. 199829 mai 2001Corvita CorporationMethod for preparation of a self-expanding stent for a medical device to be introduced into a cavity of a body
US626158328 juil. 199817 juil. 2001Atrix Laboratories, Inc.Moldable solid delivery system
US62647017 déc. 199824 juil. 2001Kensey Nash CorporationDevice and methods for in vivo culturing of diverse tissue cells
US627389729 févr. 200014 août 2001Ethicon, Inc.Surgical bettress and surgical stapling apparatus
US627792723 nov. 199821 août 2001United States Surgical CorporationComprising blocks consisting of randomly repeating units of lactide and glycolide, wherein the second block contains a larger percentage of lactide units; increased in vivo strength with no decrease in rate of bioabsorption; sutures; fibers
US62966459 avr. 19992 oct. 2001Depuy Orthopaedics, Inc.Intramedullary nail with non-metal spacers
US632581030 juin 19994 déc. 2001Ethicon, Inc.Foam buttress for stapling apparatus
US6348066 *14 août 199819 févr. 2002Corvita CorporationModular endoluminal stent-grafts and methods for their use
US6348068 *23 juil. 199919 févr. 2002Sulzer Carbomedics Inc.Multi-filament valve stent for a cardisc valvular prosthesis
US635027715 janv. 199926 févr. 2002Scimed Life Systems, Inc.Stents with temporary retaining bands
US63952938 mars 200028 mai 2002Atrix LaboratoriesBiodegradable implant precursor
US652434522 oct. 199725 févr. 2003Bionx Implants OySurgical implant
US654618813 janv. 19998 avr. 2003Sony CorporationEditing system and editing method
US658946812 mai 20008 juil. 2003Meadox Medical, Inc.Method of forming an implantable tubular prosthesis
US66240975 déc. 200023 sept. 2003Solutia Inc.Implantable fibers and medical articles
US665258519 févr. 200225 nov. 2003Sdgi Holdings, Inc.Flexible spine stabilization system
US670943622 mai 200023 mars 2004Depuy Orthopaedics, Inc.Non-metal spacers for intramedullary nail
US671693225 juil. 20016 avr. 2004Tyco Healthcare Group LpHigh consistency absorbable polymeric resin
US67199355 janv. 200113 avr. 2004Howmedica Osteonics Corp.Process for forming bioabsorbable implants
US678352919 oct. 200131 août 2004Depuy Orthopaedics, Inc.Non-metal inserts for bone support assembly
US67869082 août 20017 sept. 2004Depuy Orthopaedics, Inc.Bone fracture support implant with non-metal spacers
US680852725 mars 200226 oct. 2004Depuy Orthopaedics, Inc.Intramedullary nail with snap-in window insert
US68147537 mai 20039 nov. 2004Scimed Life Systems, Inc.Implantable tubular prosthesis
US682774325 févr. 20027 déc. 2004Sdgi Holdings, Inc.Woven orthopedic implants
US68521289 oct. 20038 févr. 2005Sdgi Holdings, Inc.Flexible spine stabilization systems
US692965925 févr. 200216 août 2005Scimed Life Systems, Inc.Method of preventing the dislodgment of a stent-graft
US702213226 févr. 20024 avr. 2006Boston Scientific Scimed, Inc.Stents with temporary retaining bands
US70411385 janv. 20059 mai 2006Sdgi Holdings, Inc.Flexible spine stabilization systems
US709790730 juil. 200329 août 2006United States Surgical Corporationpolydioxanone star polymers used as as fiber coatings, bioadhesives, tissue growth substrate or bone fusion devices
US712892714 avr. 199831 oct. 2006Qlt Usa, Inc.Emulsions for in-situ delivery systems
US722944126 févr. 200212 juin 2007Warsaw Orthopedic, Inc.Flexible systems for spinal stabilization and fixation
US732100828 août 200622 janv. 2008United States Surgical CorporationBioabsorbable branched polymers end-capped with diketene acetals
US732624926 avr. 20065 févr. 2008Warsaw Orthopedic, Inc.Flexible spine stabilization systems
US732927118 déc. 200312 févr. 2008Ethicon, Inc.High strength suture with absorbable core
US734160128 juil. 200411 mars 2008Warsaw Orthopedic, Inc.Woven orthopedic implants
US734453930 mars 200118 mars 2008Depuy Acromed, Inc.Intervertebral connection system
US7347870 *7 nov. 200025 mars 2008Bioring SaDevice for shrinking or reinforcing the heart valvular orifices
US741048818 févr. 200512 août 2008Smith & Nephew, Inc.Hindfoot nail
US74681529 mars 200423 déc. 2008Howmedica Osteonics Corp.Process for forming bioabsorbable implants
US756907621 mars 20034 août 2009Children's Medical Center CorporationAn implantable, biocompatible, synthetic/natural, polymer matrix structure shaped like a bladder having the matrix coated with biodegradable shape-setting, liquefied glycolic acid-lactic acid copolymer and cells deposited on/in the matrix to form an organized matrix/cell graft repair or replacement
US761425819 oct. 200610 nov. 2009C.R. Bard, Inc.Prosthetic repair fabric
US765500930 nov. 20042 févr. 2010Smith & Nephew, Inc.Humeral nail
US768239230 oct. 200223 mars 2010Depuy Spine, Inc.Regenerative implants for stabilizing the spine and devices for attachment of said implants
US7811332 *22 juil. 200512 oct. 2010Children's Medical Center CorporationReconstruction method for urological structures utilizing polymeric matrices
US781566125 janv. 200619 oct. 2010Tyco Healthcare Group, LpMethod and apparatus for implanting an occlusive structure
US79004845 nov. 20098 mars 2011C.R. Bard, Inc.Prosthetic repair fabric
US797235425 janv. 20065 juil. 2011Tyco Healthcare Group LpMethod and apparatus for impeding migration of an implanted occlusive structure
US801137019 déc. 20086 sept. 2011Tyco Healthcare Group LpMethod for permanent occlusion of fallopian tube
US80121728 mars 20066 sept. 2011Arthrex, Inc.High strength suture with coating and colored trace
US80667506 oct. 200629 nov. 2011Warsaw Orthopedic, IncPort structures for non-rigid bone plates
US810996714 avr. 20087 févr. 2012Depuy Mitek, Inc.High strength suture with absorbable core and suture anchor combination
US812870720 mai 20096 mars 2012Children's Medical Center CorporationBladder reconstruction
US82265985 août 200324 juil. 2012Tolmar Therapeutics, Inc.Coupling syringe system and methods for obtaining a mixed composition
US826269525 janv. 200611 sept. 2012Tyco Healthcare Group LpStructures for permanent occlusion of a hollow anatomical structure
US826318722 févr. 201111 sept. 2012Teijin LimitedComposite of support matrix and collagen, and method for production of support matrix and composite
US829829020 sept. 200430 oct. 2012Davol, Inc.Implantable prosthesis for soft tissue repair
US8328849 *1 déc. 200911 déc. 2012Zimmer GmbhCord for vertebral stabilization system
US83332011 juil. 201118 déc. 2012Covidien LpMethod for permanent occlusion of fallopian tube
US833378618 oct. 201018 déc. 2012Covidien LpMethod and apparatus for implanting an occlusive structure
US833380319 nov. 200918 déc. 2012Lifecell CorporationReinforced biologic material
US856844920 déc. 201129 oct. 2013Depuy Mitek, LlcHigh strength suture with absorbable core and suture anchor combination
US87215196 juin 200613 mai 2014Boston Scientific Scimed, Inc.Implantable mesh combining biodegradable and non-biodegradable fibers
US8741201 *9 sept. 20103 juin 2014Advanced Cardiovascular Systems, Inc.Fiber reinforced composite stents
US20100291287 *14 mai 201018 nov. 2010Degima GmbhPolymeric plate bendable without thermal energy and methods of manufacture
US20130211430 *10 févr. 201215 août 2013Novus Scientific Pte. Ltd.Multifilaments with time-dependent characteristics, and medical products made from such multifilaments
USRE3795028 mars 200031 déc. 2002Atrix LaboratoriesBiogradable in-situ forming implants and methods of producing the same
USRE3971323 janv. 20033 juil. 2007Genzyme CorporationAnd also containing water-soluble polymeric block(s), and at least one polymerizable group; used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents, plug leaks in tissue, prevent adhesion formation after surgical procedures, and protect or seal tissue surfaces
USRE4450112 août 201017 sept. 2013Smith & Nephew, Inc.Hindfoot nail
DE3047573C2 *4 juin 198028 juin 1990Staffan BowaldTitre non disponible
DE3433331A1 *11 sept. 198428 mars 1985Materials Consultants OyChirurgische vorrichtung zum immobilisieren von knochenfrakturen
DE3913926A1 *27 avr. 198931 oct. 1990Heinz Helmut Dr Med WernerVascular prosthesis, esp. of PET with resorbable plastic coatings - esp. of poly:lactide, applied as soln. then treatment with non-solvent
EP0050215A1 *18 sept. 198128 avr. 1982American Cyanamid CompanyModification of polyglycolic acid to achieve variable in-vivo physical properties
EP0202444A2 *7 avr. 198626 nov. 1986American Cyanamid CompanyProsthetic tubular article
EP0334024A2 *20 févr. 198927 sept. 1989American Cyanamid CompanyProsthetic tubular article
EP0701823A218 sept. 199520 mars 1996United States Surgical CorporationAbsorbable polymer and surgical articles fabricated therefrom
EP0786259A217 janv. 199730 juil. 1997United States Surgical CorporationAbsorbable polymer blends and surgical articles fabricated therefrom
EP1361835A1 *16 juil. 200119 nov. 2003Bionx Implants, Inc.Self-expanding stent with enhanced radial expansion and shape memory
EP1543782A1 *20 déc. 200422 juin 2005Ethicon, Inc.High strength suture with absorbable core
EP2036582A121 juil. 199518 mars 2009United States Surgical CorporationBiobsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
EP2166989A1 *13 juin 200831 mars 2010BioDynamics LLCImplantable mesh for musculoskeletal trauma, orthopedic reconstruction and soft tissue repair
EP2301597A121 juil. 199530 mars 2011United States Surgical CorporationBioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
WO1982001647A1 *30 oct. 198127 mai 1982Robert L KasterVascular graft
WO1986000533A1 *10 juil. 198530 janv. 1986Univ GroningenBone implant
WO1987000419A1 *29 mai 198629 janv. 1987Minnesota Mining & MfgSemiabsorbable bone plate spacer
WO1994003117A1 *27 juil. 199317 févr. 1994Dental Marketing Spec IncBone augmentation method and apparatus
WO1996022055A129 déc. 199525 juil. 1996Inbae YoonSurgical stapling system and method of applying staples from multiple staple cartridges
WO1998018408A122 oct. 19977 mai 1998Bionix Implants OySurgical implant
WO2004006808A2 *17 juil. 200322 janv. 2004Proxy Biomedical LtdSoft tissue implants and methods for making same
WO2006002340A2 *23 juin 20055 janv. 2006Charles A HowlandControlled absorption biograft material for autologous tissue support
WO2007070141A112 sept. 200621 juin 2007Proxy Biomedical LtdSoft tissue implants and methods for making same
WO2007145974A2 *5 juin 200721 déc. 2007Boston Scient Scimed IncImplantable mesh combining biodegradable and non-biodegradable fibers
Classifications
Classification aux États-Unis606/154, 623/1.49, 428/373, 606/155
Classification internationaleA61F13/15, A61L27/18, C08G63/06, A61F13/00, A61F13/20, A61L17/12, A61B17/00, D01F6/62
Classification coopérativeA61F13/20, A61L27/18, A61F2013/00221, A61L17/12, D01F6/625, A61F13/551, A61F2013/00157, C08G63/06, A61B2017/00004
Classification européenneA61L27/18, A61L17/12, C08G63/06, D01F6/62B